Clin2
NCT07662525Possibly a fitNot yet recruiting

Atorvastatin, NAC and romiplostim for ITP

Immune Thrombocytopenic Purpura

Part of Blood & lymphatic, Immune system & allergy clinical trials.

This trial tests a combination of two common medicines (atorvastatin and NAC) plus romiplostim to treat ITP when steroids have stopped working or stopped working. It may help raise your platelet counts.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
50 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You have been diagnosed with primary ITP.
  • You are 18 years old or older.
  • You tried steroid treatment (like prednisone) for ITP, and it didn't work or your ITP came back.
  • Your platelet count is below 30,000.
  • You do not have active cancer, certain infections (hepatitis, HIV), or serious heart or liver conditions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06992128Recruiting· Phase 2
Romiplostim plus steroids for newly diagnosed ITP

This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.

Tianjin, Tianjin Municipality
NCT06658834Recruiting· Phase 2
Romiplostim for newly diagnosed ITP in adults

This trial tests a medicine called romiplostim (Nplate) as a first treatment for adults newly diagnosed with ITP. It aims to see if it can safely raise platelet counts and reduce bleeding risk.

Tianjin, Tianjin Municipality
NCT04518475Recruiting· Phase 4
Eltrombopag with rituximab versus eltrombopag alone for ITP

This trial compares two treatment approaches for adults with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It looks at whether adding rituximab to eltrombopag helps control ITP better and more safely.

Tianjin
NCT07687134Not yet recruiting· Phase 2
Eltrombopag plus telitacicept for difficult ITP

This trial tests whether adding a new drug (telitacicept) to a standard platelet booster (eltrombopag) works better than eltrombopag alone for adults whose ITP has not responded to steroids.

Tianjin, Tianjin Municipality
NCT07057778Not yet recruiting· Phase 2
Iguratimod plus low-dose rituximab for hard-to-treat ITP

This trial tests whether adding iguratimod (a medicine that helps control immune system activity) to a low dose of rituximab (a targeted therapy for immune cells) works better than low-dose rituximab alone for people with ITP that has not responded to steroid treatment or that comes back after steroids are stopped.

Beijing
NCT07788456Recruiting· Phase 4
Sequential combination therapy for newly diagnosed ITP in adults

This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.

Tianjin

Hear when a new Immune Thrombocytopenic Purpura trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.